Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) and may include paid advertising.

• SpaceX’s record June 2026 IPO put a public spotlight on space, yet most of the sector’s frontier companies remain private and out of reach for public investors
• Antaris, a software-defined space infrastructure company backed by Planet Ventures, signed a memorandum of agreement with Transcelestial to develop and flight-test a combined surveillance and optical-communications architecture on its JANUS-2 mission in late 2026
• Planet Ventures gives public-market investors exposure to private space companies such as Antaris, Relativity Space, and General Astronautics that are typically accessible only to venture and institutional capital

The biggest story in space this year did not happen in orbit. On June 12, 2026, SpaceX completed the largest initial public offering in history, pricing at $135 per share and debuting at a valuation approaching $1.8 trillion. For the first time, everyday investors could buy a direct stake in the company that drove launch costs lower and reshaped the economics of space.

Yet the listing also exposed a gap. SpaceX is now public, but many of the companies building the next layer of space economy remain private and largely inaccessible to public-market investors. While rockets captured the first chapter of commercial space development, the next phase is increasingly focused on software, communications, robotics, and the infrastructure required to manage rapidly growing networks of satellites and space-based systems.

Closing that gap is the strategy behind Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF), an investment issuer focused on providing shareholders with exposure to private companies operating across multiple segments of the expanding space economy. One of those portfolio companies recently achieved a milestone that highlights where the industry may be heading next.

The Operating System for Space

Antaris, a private space technology company backed by Planet Ventures, is building a software-defined platform for designing, simulating, deploying, and operating satellite missions. Rather than focusing on a single spacecraft or payload, the company’s technology is intended to simplify how entire constellations are built and managed across multiple hardware providers and orbital environments.

The concept mirrors the evolution of cloud computing on Earth. As digital infrastructure became increasingly complex, software platforms emerged to simplify deployment, management, and scalability. Antaris is applying a similar approach to space operations, where satellite operators increasingly require flexible software capable of managing missions across diverse systems and suppliers.

Investors have taken notice. Antaris completed a $28 million Series A financing and counts investors including Lockheed Martin Ventures and WestWave Capital among its backers. The company’s mission is straightforward: make space infrastructure easier to build, deploy, and operate.

A Strategic Milestone for Antaris

That vision moved forward on May 6, 2026, when Antaris announced a memorandum of agreement with Transcelestial, a company developing advanced optical communications technology designed to move data between satellites at high speed.

Together, the companies plan to develop and demonstrate persistent intelligence, surveillance, and reconnaissance (“ISR”) architecture integrated with high-throughput optical communications in low Earth orbit. The initiative is expected to be flight-validated aboard Antaris’ JANUS-2 mission, currently targeted for the fourth quarter of 2026.

The agreement highlights a broader shift underway across the space economy. The challenge is no longer simply putting sensors into orbit. Modern satellite networks must collect, process, transmit, and act upon enormous volumes of information in near real time. As constellations expand and applications become more sophisticated, software and communications infrastructure increasingly become the critical layer that enables everything else.

Optical communications have attracted growing interest because they can transmit significantly more data than traditional radio-frequency systems while reducing latency and improving security. Combined with persistent sensing capabilities, these technologies could support real-time decision-making across commercial, government, and defense applications.

For Antaris, the Transcelestial agreement represents validation that software-defined mission management and high-speed communications are becoming foundational components of next-generation space infrastructure.

A Different Way to Invest in the Space Economy

The SpaceX IPO reinforced a challenge many investors face: some of the most innovative companies in the industry remain private. Access is often limited to venture capital firms, institutional investors, and specialized private funds.

Planet Ventures has built its strategy around addressing that gap. Rather than operating a single technology business, the company invests across multiple segments of the space economy, including launch systems, mission-management software, orbital infrastructure, robotics, and emerging aerospace technologies.

Its portfolio includes investments in Antaris, General Astronautics, Mantis Space, and other developing space-focused businesses. Collectively, those investments provide exposure to multiple layers of the commercial space ecosystem rather than a single technology theme.

The opportunity is substantial. According to World Economic Forum estimates, the global space economy was valued at approximately $630 billion in 2025 and is projected to exceed $1.8 trillion by 2035. The Space Foundation estimates that commercial activity already accounts for roughly 78% of the sector, highlighting the growing role of private enterprise in shaping the future of space.

Building the Infrastructure Behind the Headlines

Space headlines often focus on rocket launches, lunar missions, and billionaire founders. SpaceX’s historic IPO fit squarely into that narrative. Yet history suggests that some of the most durable value creations occur in the infrastructure layer that enables those headline-grabbing achievements to scale.

As satellite deployments accelerate and mission complexity continues to increase, the platforms responsible for coordinating communications, operations, and decision-making may become as important to the space economy as operating systems are to personal computing.

The JANUS-2 mission remains ahead, and the companies within Planet Ventures’ portfolio are still executing early-stage growth strategies. Yet SpaceX’s public debut may have reinforced a simple reality: much of the next decade’s value creation in space is likely still occurring behind private-company doors. Planet Ventures’ strategy is built around gaining exposure to those opportunities before they become household names.

For more information, visit www.PlanetVenturesInc.com.

NOTE TO INVESTORS: The latest news and updates relating to PNXPF are available in the company’s newsroom at https://ibn.fm/PNXPF

Disclaimer

Investor Brand Network (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Planet Ventures Inc. will make aggregate payments of $100,000  to us to provide marketing services for a term of 1 year. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of applicable securities legislation. Such statements include, without limitation, statements regarding: Planet Ventures’ investment strategy and objectives; anticipated developments in the commercial space industry, including the growth of orbital energy and space robotics markets; the projected growth of the global space economy; Planet Ventures’ expectations regarding the strategic importance of its investments in Mantis Space and General Astronautics; the anticipated role of orbital energy technologies and robotic servicing systems in future in-orbit operations; and the potential for these technologies to become foundational to the next generation of commercial space activity.

Forward-looking statements are not guarantees of future performance. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this document are made as of the date hereof and Planet Ventures undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

Risk Factors

Investing in Planet Ventures and its portfolio companies involves a high degree of risk. The following is a summary of key risk factors. This is not an exhaustive list, and additional risks may exist that are not currently known:

• Early-Stage Investment Risk. Portfolio companies have limited operating histories and are pre-revenue. Investments are speculative and may result in a total loss of capital.
• Technology Risk. The orbital energy and lunar habitation technologies underlying the Company’s investments are unproven at commercial scale and may not be successfully developed or deployed.
• Regulatory Risk. Space sector operations require licenses and approvals from domestic and international regulatory bodies. Failure to obtain or maintain these could materially delay or prevent operations.
• Market Risk. Commercial demand for in-space power systems and lunar services has not been established at scale. Projected market growth may not be realized within anticipated timeframes.
• Liquidity Risk. Investments in private, early-stage companies are illiquid. There is no guarantee of a market for these securities or the ability to exit on favorable terms.
• Capital Risk. Portfolio companies may require additional funding that may not be available, or may be available only on dilutive or restrictive terms.
• Macroeconomic and Geopolitical Risk. Adverse macroeconomic conditions or geopolitical developments could disrupt the Company’s investment strategy or the operations of portfolio companies.
• Key Personnel Risk. The Company’s performance depends in part on retaining key personnel and advisors. Loss of key individuals could adversely affect the Company’s operations and investment activities.

About InvestorWire

Disseminated on behalf of  Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.

• Top gold-producing countries are showing strain of widespread government, cost and environmental pressures.
• These pressures strengthen the case for secure, transparent and infrastructure-supported gold development in the United States.
• Existing mine infrastructure, historical production, oxide material and location in a leading U.S. gold state may give Lahontan’s Santa Fe project a different development profile.

Global gold supply is entering a more complicated era, shaped not only by geology and discovery rates but also by government policy, rising operating costs, safety enforcement, environmental oversight and growing pressure for producing countries to capture more value at home. In that setting, Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF), a Canadian mineral exploration company with four gold and silver exploration properties in Nevada’s Walker Lane, is advancing the Santa Fe Mine project and related assets in one of the United States’ most established gold-producing jurisdictions.

The pressure is visible even in the world’s largest producing country. The U.S. Geological Survey noted that China, Russia, Australia, Canada and the United States were the leading gold producers in 2025, in descending order, and together accounted for 41% of estimated global output. Yet China’s own production base showed strain in early 2026. Reuters reported that China’s total gold production from domestic and imported raw materials was 136.230 metric tons in the first quarter of 2026, down 3.3% year over year, while domestic production fell 7.1% to 81.065 metric tons. The report cited the China Gold Association and noted that the decline came “as safety inspections led some smelters to suspend production for maintenance.”

That kind of decline matters because it suggests supply growth can be constrained even when gold prices are high. Safety reviews, environmental regulation, mine depletion and maintenance-related disruptions can all limit production from mature districts. For investors and operators, the result is a market in which the availability of ounces may depend less on price alone and more on whether projects are in jurisdictions with clear rules, existing infrastructure and realistic pathways to development.

At the same time, many resource-rich countries are revisiting the economics of mining in response to high gold prices. Ghana, Africa’s top gold producer, has become a clear example. Earlier this year, Reuters reported that Ghana planned to scrap long-term mining investment stability agreements and double royalties under broad mining-sector reforms. The proposed structure would raise royalties from the current 3–5% range to 9–12%, with the top rate applying if gold reaches $4,500 per ounce or higher. The reforms also include tougher local-content rules, and Reuters quoted Ghana Minerals Commission acting CEO Isaac Tandoh as saying, “Renewal is conditional, not automatic.”

The local-content trend has also continued. Ghana’s mining regulator has given international companies including Newmont, AngloGold Ashanti and Zijin until December 2026 to shift mining operations to local contractors or face sanctions. Ghana revised local ownership rules in January 2025, requiring surface mining to be undertaken by fully Ghanaian-owned firms and underground mining by companies with at least 50% Ghanaian ownership. In addition, African governments have been tightening mining rules to extract more revenue amid rising metals prices.

For mining companies, these changes may support national development goals, but they can also raise costs, complicate contracting and increase uncertainty around long-term project economics. Royalty increases, local procurement mandates and ownership requirements can change the risk profile of projects, particularly for new mines that require major upfront capital. When those rules shift after companies have already invested heavily, the investment case can become more difficult to underwrite.

Illegal mining is another growing challenge. In Latin America, illegal gold mining is spreading into new parts of Peru’s Amazon, advancing along remote rivers and into Indigenous territories. Reports note that the expansion is accelerating deforestation, contaminating rivers with mercury and exposing remote communities to violence and organized crime.  In Brazil, billions of dollars of gold were being extracted illegally from the Amazon rainforest despite enforcement efforts.

These pressures strengthen the case for secure, transparent and infrastructure-supported gold development in the United States. Nevada remains central to that story. According to the U.S. Geological Survey’s 2026 gold summary, Nevada was the leading gold-producing state, accounting for about 64% of total domestic production. That makes Nevada not just a mining district but the foundation of U.S. gold supply.

This is where Lahontan Gold’s portfolio becomes relevant. The company’s Santa Fe Mine has historic production of 359,202 ounces of gold and 702,067 ounces of silver from open-pit mining with heap-leach processing between 1988 and 1995. Lahontan also reports a National Instrument 43-101 compliant indicated mineral resource of 1.539 million gold-equivalent ounces and an inferred mineral resource of 411,000 gold-equivalent ounces, all pit constrained.

Santa Fe’s brownfield profile is important in a market where new mines can face long timelines and uncertain permitting. Lahontan’s Santa Fe project is a 28.3-square-kilometer land package that includes 307 unpatented lode mining claims, 67 unpatented mill site claims and 24 patented lode mining claims. The company also notes that past production came from open pits processed by heap leach and reported recoveries of approximately 70% for gold and approximately 30% for silver. In addition, the company’s 2026 objectives include completing an updated mineral resource estimate and preliminary economic assessment, advancing mine permitting with the objective of commencing construction in 2027, continuing work at West Santa Fe and drill testing historic heap-leach pads to evaluate residual gold and silver mineralization for potential future reprocessing.

Those attributes are especially relevant as international hurdles rise. Existing mine infrastructure, historical production, oxide material and location in a leading U.S. gold state may give Santa Fe a different development profile than greenfield projects in jurisdictions facing royalty resets, local-content changes, illegal mining exposure and supply-chain uncertainty. Lahontan still faces the normal risks associated with exploration, permitting, financing and development, but its strategy is aligned with a broader market need for reliable Western gold supply.

As gold supply becomes more difficult to expand globally, the market may place increasing value on brownfield projects in stable jurisdictions with known mineralization and established mining histories. Lahontan Gold is seeking to occupy that space through Santa Fe and its broader Walker Lane portfolio. In a world where production in major countries is being pressured by safety reviews, environmental constraints, fiscal changes and informal mining risks, Nevada-based gold development could become more strategically important, and Lahontan’s work at Santa Fe positions the company as a powerful participant in that shift.

For more information, visit the company’s website at www.LahontanGoldCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to LGCXF are available in the company’s newsroom at ibn.fm/LGCXF

• Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics, with pharmaceutical companies continuing to commit substantial capital to preclinical and early-stage innovation.
• The Jazz Pharmaceuticals–AbCellera collaboration illustrates how differentiated antibody technologies can command significant financial commitments before entering clinical development.
• VERAXA Biotech AG is positioning its technology platform across both ADCs and T-cell engagers, two therapeutic modalities that continue to attract strategic partnerships and acquisitions.
• Platform technologies and individual drug candidates both represent potential avenues for future partnering, licensing, and collaboration agreements.
• Recent transactions across the sector demonstrate that pharmaceutical companies are actively seeking access to differentiated antibody engineering capabilities rather than waiting for late-stage clinical assets.

Biotechnology investors often focus on clinical milestones, regulatory approvals, and commercial launches. Yet in antibody therapeutics, some of the largest value-creating events occur much earlier. Strategic licensing agreements, research collaborations, and acquisitions, have become important catalysts for companies developing differentiated technology platforms, and have resulted in significant market value shifts. That trend has been particularly evident in antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics. Pharmaceutical companies continue to pursue external innovation as they seek new approaches for treating difficult cancers, creating an environment in which promising technology platforms can attract significant commercial interest well before pivotal clinical trials.

One recent example came from Jazz Pharmaceuticals and AbCellera, which announced a collaboration to discover next-generation multispecific T-cell engaging antibodies. Under the agreement, Jazz receives exclusive rights to develop and commercialize products emerging from the collaboration, while AbCellera is eligible for an upfront payment, research funding, development and commercial milestone payments that could total as much as approximately $2.7 billion, in addition to tiered royalties should products reach the market. The collaboration illustrates the scale of investment pharmaceutical companies remain willing to commit for differentiated antibody discovery capabilities even before clinical development begins, a flashing light for attentive investors (https://ibn.fm/kX2wa).

From an investor standpoint, the significance extends beyond the companies directly involved. The agreement reinforces the continued appetite among established pharmaceutical companies to secure access to novel antibody engineering technologies capable of generating future product pipelines.

The deal also demonstrates that this competitive environment is not limited to the largest global pharmaceutical companies. Jazz, while a substantial commercial oncology company, competes in an increasingly active market where companies across the industry are seeking innovative external technologies to strengthen future portfolios.

The same pattern has emerged in antibody-drug conjugates. Gilead Sciences recently agreed to acquire Tubulis, a German biotechnology company focused on next-generation ADC technologies, in a transaction valued at up to approximately $5 billion (https://ibn.fm/SwtCZ). Tubulis was founded around research originating from German academic institutions, highlighting how university-based scientific innovation can ultimately attract major strategic interest from global pharmaceutical companies.

VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, occupies a similar part of the innovation ecosystem. The company is developing a diversified oncology pipeline built around next-generation antibody therapeutics, including bispecific ADCs, bispecific T-cell engagers and engineered antibody formats predominantly based on its patented BiTAC platform. Rather than focusing exclusively on a single therapeutic approach, VERAXA is advancing multiple antibody platforms that could potentially support future collaborations across several oncology indications.

Its proprietary BiTAC platform reflects growing interest in increasingly sophisticated antibody engineering. As pharmaceutical companies seek therapies capable of improving efficacy while reducing off-target toxicity, bispecific antibodies, targeted payload delivery and immune cell engagement have become areas receiving sustained research investment.

This creates two potential strategic pathways that companies like VERAXA may pursue over time. The first involves platform partnerships similar to the Jazz-AbCellera collaboration. Large pharmaceutical companies increasingly license access to proprietary antibody discovery technologies capable of generating multiple therapeutic candidates over many years. These agreements frequently include upfront payments, research funding, milestone payments and future royalties tied to commercial success.

The second pathway centers on individual development programs. As drug candidates mature and generate additional preclinical or clinical data, pharmaceutical companies may pursue licensing transactions, co-development agreements or outright acquisitions focused on specific therapeutic assets.

Neither outcome is guaranteed when it comes to biotechnology development, with high risk being the unavoidable cost of high potential. Companies must continue generating compelling scientific data, expanding intellectual property portfolios, advancing manufacturing capabilities and meeting regulatory milestones before potential commercial partnerships become realistic. However, recent transactions demonstrate that pharmaceutical companies are increasingly willing to evaluate differentiated technologies well before products reach late-stage clinical development.

VERAXA appears to be building toward that position through continued investment in scientific validation, patent filings and development infrastructure. The company’s strategy of maintaining exposure to both ADCs and T-cell engagers aligns with two therapeutic categories that continue to generate significant pharmaceutical investment.

The broader transaction landscape reinforces this trend. Among recent ADC transactions, Pfizer entered a strategic licensing and collaboration agreement with Innovent Biologics valued at up to approximately $10.5 billion to co-develop multiple oncology programs. Eli Lilly acquired CrossBridge Bio to expand its dual-payload ADC capabilities, while Roche expanded its collaboration with MediLink Therapeutics around a B7-H3-targeted ADC. Earlier, Avenzo Therapeutics licensed DualityBio’s EGFR/HER3 ADC in a transaction that included milestone payments exceeding $1 billion.

Activity has also remained strong across T-cell-based immunotherapies. Eli Lilly announced plans to acquire Kelonia Therapeutics to strengthen its in vivo CAR-T platform. Gilead expanded its immunology portfolio through the acquisition of Ouro Medicines, including its BCMAxCD3 T-cell engager program. Candid Therapeutics also entered the market with substantial financing focused on developing T-cell engager therapies for autoimmune diseases.

Collectively, these transactions suggest that pharmaceutical companies continue to view antibody engineering as one of the most active areas for external innovation. While individual technologies differ, the willingness to commit substantial capital at relatively early stages reflects confidence that next-generation antibody therapeutics will remain central to future oncology development.

For VERAXA shareholders, the relevance lies less in predicting any single transaction than in understanding the commercial environment in which the company operates. Recent collaborations and acquisitions demonstrate that differentiated antibody platforms can attract significant strategic interest before reaching late-stage clinical development, provided they continue to generate compelling scientific evidence and demonstrate clear technological advantages.

For more information, visit the company’s website at www.Veraxa.com.  

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.

• MindBio kiosks use artificial intelligence and voice analysis to detect potential intoxication and fatigue in workplace environments.
• The company is targeting industries such as mining, aviation, construction, transportation, and law enforcement, where safety-sensitive operations require large-scale screening.
• MindBio’s AI models have been trained on more than 50 million data points and analyze over 140 acoustic markers associated with impairment.
• Prototype kiosks are entering testing, validation, and data-analysis phases, before broader commercial deployment.
• The company is positioning this important new technology as a faster and less invasive alternative to traditional drug and alcohol testing methods.

MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company, has reached a new development milestone with the completion and delivery of its first prototype Edge AI Intoxication and Fatigue Detection Kiosks, advancing the company’s effort to commercialize voice-based impairment detection technology for workplace safety applications. According to a recent company announcement, the kiosks combine proprietary hardware and software designed to assess intoxication and fatigue through short voice samples analyzed by artificial intelligence (https://ibn.fm/cnaJn).

The prototypes have now entered a testing and validation phase that will involve collaboration with industry participants, speech specialists and software engineers. The objective is to refine the company’s predictive models and evaluate performance under real-world operating conditions before broader commercial deployment.

The launch comes as employers across multiple industries face increasing pressure to improve workplace safety while managing the costs and operational burdens associated with conventional drug and alcohol testing programs.

Traditional screening methods, including breathalyzers, saliva tests, urine analysis and laboratory testing, remain widely used but often require significant administrative resources, trained personnel and processing time. For large employers operating in safety-sensitive sectors, testing hundreds or even thousands of workers can create logistical challenges.

MindBio is pursuing a different approach. Rather than relying on biological samples, the company’s technology analyzes vocal characteristics that may change when an individual is impaired by alcohol, drugs or fatigue. According to the company, its artificial intelligence platform evaluates more than 140 acoustic markers and has been trained using a dataset exceeding 50 million data points collected through years of research.

The result is intended to be a rapid screening process that can be completed through a standard microphone, potentially reducing the need for more invasive testing while enabling organizations to screen large workforces efficiently.

MindBio’s initial commercialization efforts are focused on industries where impairment management is already a regulatory and operational priority. Mining operations represent a particularly attractive market. Many mines operate around the clock, employ large workforces and often function in remote environments where safety protocols are critical. Conducting traditional drug and alcohol testing at scale can be both costly and time consuming.

The company has also identified aviation, construction, heavy transportation and law enforcement as target sectors. These industries share a common need for rapid, scalable and repeatable screening processes that can help identify individuals who may require additional evaluation.

MindBio recently expanded its platform beyond intoxication detection with the addition of fatigue recognition capabilities, reflecting growing industry interest in managing fatigue-related workplace risks alongside substance impairment.

The kiosk deployment follows several recent developments within MindBio’s commercialization strategy. Earlier this month, the company announced the launch of Intox AI(TM), its lead enterprise software platform designed to detect alcohol intoxication, drug use and fatigue through voice analysis. The platform is intended to serve as the analytical engine behind future kiosk deployments and enterprise integrations.

MindBio has also filed patent applications covering aspects of its AI-powered voice analysis technology, reflecting management’s effort to build an intellectual property portfolio around the platform as commercialization advances.

The company is entering a market that continues to expand as employers adopt new safety technologies and regulators place greater emphasis on workplace compliance. Demand for impairment detection tools is being driven by industries where employees operate heavy machinery, manage transportation systems or perform other safety-critical tasks. Organizations are increasingly seeking solutions that can improve efficiency while maintaining testing standards.

MindBio’s strategy centers on providing a scalable screening layer that can be deployed at facility entrances, worksites and operational checkpoints. Workers provide a short voice sample, and the system generates an assessment within seconds. Those flagged for potential impairment can then undergo additional evaluation using existing testing protocols.

For more information, visit the company’s website at www.MindBioTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

• Quantum BioPharma executive co-chairman and co-founder Anthony Durkacz appeared as a guest on the BioMedWire Podcast.
• Durkacz outlined the company’s strategy for advancing Lucid-MS, the company’s lead drug candidate for multiple sclerosis.
• The Quantum BioPharma exec also provided an update on unbuzzd, the company’s innovative, clinically validated alcohol metabolism accelerator designed to help sober people up faster.

Executive thought leadership has become an increasingly important component of corporate communications, particularly in highly specialized industries such as biotechnology. Through podcasts, interviews and other educational forums, company leaders can explain complex technologies, discuss development strategies and provide context that is often difficult to capture in traditional press releases. That approach was recently on display when Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) executive co-chair and co-founder Anthony Durkacz appeared as a guest on the BioMedWire Podcast.

Quantum BioPharma is a biopharmaceutical company focused on developing treatments for neurodegenerative, metabolic and alcohol-misuse disorders, with Lucid-MS and its ownership in commercially product unbuzzd(TM). During the interview, Durkacz outlined the company’s strategy for advancing Lucid-MS, the company’s lead drug candidate for multiple sclerosis (“MS”); discussed the market opportunity for unbuzzd; and reviewed key objectives planned for this year.

Durkacz focused much of the discussion on Lucid-MS. Explaining the rationale behind the program, he noted that “Quantum BioPharma is focused on a drug candidate that is trying to address an issue that exists today for people that suffer from multiple sclerosis.” He went on to describe the progressive nature of the disease and the debilitating impact it can have on mobility and quality of life.

“What our main drug candidate focus, Lucid-MS, is trying to do is reverse damage that’s been done to people’s mobility,” he stated, noting that almost three million people are diagnosed with MS worldwide with almost one million in the USA. “We believe that is something that is not addressed in any drug or therapy today in the world.”

The podcast discussion also covered the company’s development plans for Lucid-MS, which includes an upcoming clinical trial. “We filed our IND for a phase 2 trial for MS patients,” Durkacz explained. Once approved, “This will be the first time that Lucid-MS would be taken by a person with MS.”

“This will be the first time we will be able to see the reaction . . . and determine whether there are any efficacy signals that match what we’ve seen in our animal models over the past decade,” he continued. “That is what we are laser focused on right now.” The advancement into patient studies marks an important milestone for the program as the company seeks to gather additional data regarding safety and potential life changing therapeutic effects.

In addition to discussing its therapeutic pipeline, the Quantum BioPharma exec used the interview to provide an update on unbuzzd, a product the company developed that has been licensed and was designed and clinically proven to accelerate alcohol metabolism. Durkacz explained that the product is already commercially available in the United States and forms part of the company’s broader strategy of building value through both clinical-stage biotechnology assets and commercial opportunities. The combination of therapeutic development programs and commercial products gives the company exposure to multiple potential growth drivers while advancing its longer-term pharmaceutical objectives.

Durkacz and podcast host Stuart Smith also discussed the company’s broader mission. The company is focused on developing innovative solutions for challenging neurodegenerative and metabolic disorders as well as alcohol-misuse conditions. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma continues to advance Lucid-MS. Meanwhile, the company maintains an ownership interest in unbuzzd Wellness Inc. and continues to participate in the commercial growth of the unbuzzd brand.

The BioMedWire Podcast focuses on conversations with executives and industry experts involved in pharmaceutical and biotechnology innovation. The format provides an opportunity for management teams to discuss scientific programs, business strategies and industry trends in greater detail than is typically possible through standard corporate communications.

As biotechnology continues to become increasingly complex and competitive, educational platforms such as podcasts are emerging as valuable tools for corporate communication. For companies developing novel therapies, direct discussions with knowledgeable executives can help investors, industry observers and potential partners gain a deeper understanding of both the science and the business strategy behind emerging innovations. Quantum BioPharma’s recent BioMedWire appearance illustrates how executive engagement can complement traditional investor relations efforts while providing a more detailed look at the company’s research programs, commercial initiatives and anticipated milestones for the year ahead.

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.

• The global rare earth elements market is projected to grow from roughly $14 billion in 2025 to more than $41 billion by 2034, driven by accelerating demand from EV traction motors, wind turbines, consumer electronics, and defense applications
• China continues to dominate rare earth mining and processing capacity, leaving Western manufacturers exposed to persistent supply concentration risk as governments push to build alternative supply chains
• Canamera Energy Metals raised approximately $10.2 million over four months ending March 2026 and is advancing active exploration programs across seven rare earth and uranium assets in Brazil, the United States, and Canada

The rare earth supply story has moved beyond long-term strategic concern and into immediate industrial planning. Electric vehicles, wind turbines, advanced electronics, and modern defense systems all rely on rare earth inputs that remain heavily concentrated in a small number of global supply channels. Demand projections continue to move higher, but bringing meaningful new supply online remains a slow and capital-intensive process. That imbalance is creating a widening opportunity for developers positioned in jurisdictions seeking to diversify critical mineral supply chains.

Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF) is operating within that emerging window, building a multi-jurisdiction portfolio of rare earth and uranium assets across Brazil, the United States, and Canada as Western governments and manufacturers search for alternative supply sources.

A Structural Supply Problem

The long-term rare earth demand thesis remains difficult to ignore.

Global rare earth elements market projections suggest the sector could expand from approximately $14 billion in 2025 to more than $41 billion by 2034, supported by broad-based growth in permanent magnet demand. Electric vehicle adoption remains a major catalyst, with each traction motor requiring rare earth magnet materials containing elements such as neodymium and praseodymium. Wind power infrastructure adds another major layer of demand, particularly offshore installations where magnet intensity is significantly higher.

Defense applications add further pressure.

Rare earth elements are essential in radar systems, missile guidance, communications infrastructure, and other advanced military technologies, making supply chain security a strategic issue rather than simply an industrial one.

Supply growth, however, operates on a different timeline.

China still maintains dominant control over global rare earth mining, refining, and magnet manufacturing capacity. While major Western players including MP Materials, Lynas, and Iluka continue building out alternative infrastructure, meaningful production diversification remains years away in many cases. New greenfield projects often require extended permitting timelines, technical de-risking, infrastructure investment, and substantial capital commitments before reaching commercial output.

That leaves a supply gap between rising demand and available Western production.

Why Ionic Clay Projects Matter

Not all rare earth projects are built the same.

Brazilian ionic adsorption clay deposits have become increasingly relevant because they may offer a potentially faster and less capital-intensive development pathway compared with traditional hard-rock rare earth operations.

In these systems, rare earth elements are loosely bound to clay particles near surface, allowing extraction methods that can be materially less complex than conventional hard-rock mining and processing routes. That distinction has attracted growing investor and industry attention as supply chain diversification becomes more urgent.

Brazil also offers additional advantages, including established mining infrastructure, favorable geology, and increasing strategic relevance in global critical minerals development.

That backdrop helps explain Canamera’s focus in the region.

Canamera’s Expanding Platform

Canamera is building exposure through multiple rare earth opportunities while maintaining geographic diversification across the Americas.

In Brazil, the company is advancing ionic clay-hosted rare earth exploration at Turvolândia and Patos. At Turvolândia, Canamera completed the initial 350-meter phase of a planned 1,000-meter auger drill campaign, with prior disclosed intervals exceeding 6,000 ppm total rare earth oxide, suggesting characteristics associated with ionic clay mineralization. The remaining program is underway, with assay results expected in the near term.

The Patos Project represents another Brazilian ionic clay opportunity currently undergoing due diligence drilling to support acquisition decisions.

Beyond Brazil, the company is advancing the Iron Hills critical minerals project in Colorado through 3D geophysical modeling while progressing uranium work at Great Divide in Wyoming.

Its Canadian portfolio adds further optionality.

Ontario-based projects including Schryburt Lake, Garrow, and Waterslide are each moving through technical studies, airborne surveys, permitting pathways, and early exploration programs.

That portfolio breadth is notable, but execution requires capital.

Canamera reported raising approximately $10.2 million over the past four months, giving the company financial flexibility to fund multiple active exploration initiatives while maintaining operational momentum across jurisdictions.

The Junior Developer Window

Large-scale rare earth supply diversification will likely be led by major producers and integrated processors. That is already happening.

But large-scale projects take time.

In the interim, junior developers with capital, active exploration programs, and strategically positioned assets may benefit from heightened industry attention, stronger funding conditions, and potential partnership interest as supply chain participants seek future sources of material.

Rare earth demand continues rising, supply diversification has become a geopolitical priority, and developers capable of advancing credible projects are operating in a market that increasingly values optionality.

For more information, visit the company’s website at CanameraMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMETF are available in the company’s newsroom at ibn.fm/EMETF

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This document contains “forward-looking information” within the meaning of applicable securities legislation, including statements regarding: the Company’s planned exploration activities on its projects; the anticipated timing and completion of the earn-in milestones under the Option Agreement; the Company’s ability to make required cash and share payments and incur required exploration expenditures; the geological prospectivity of its projects; and the Company’s exploration strategy.

Forward-looking information is based on assumptions, estimates, and opinions of management at the date the statements are made and is subject to a variety of risks and uncertainties that could cause actual results to differ materially from those anticipated or projected. These assumptions include, without limitation: the Company’s ability to raise sufficient capital to fund its exploration programs and option payments; favourable regulatory conditions; continued access to its projects; and general economic conditions.

Important risk factors that could cause actual results to differ materially include, but are not limited to: uncertainties related to raising sufficient financing; the inherently speculative nature of mineral exploration; title risks; environmental and permitting risks; and fluctuations in uranium prices. Additional risk factors affecting the Company can be found in the Company’s continuous disclosure documents available at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information.

• American Fusion(TM) continues development of its 5MW pre-production Texatron(TM) Fusion Engine(TM) and is progressing toward planned testing activities in Texas.
• Regulatory engagement with the Texas Department of State Health Services remains underway as the company advances certification and licensing requirements.
• The company is expanding its intellectual property strategy to protect future innovations involving reactor architecture, plasma systems, and commercial deployment methods.
• Through its wholly owned subsidiary Kepler Fusion Technologies, the company is developing multiple Texatron(TM) system designs aimed at modular energy deployment.
• The company’s broader commercialization strategy focuses on scalable fusion systems for industrial, commercial, and grid-related energy applications.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, has filed an additional patent application as it advances the development of its Texatron(TM) Fusion Engine(TM) platform, marking another step in the company’s effort to build a portfolio of proprietary technologies around future fusion energy systems (https://ibn.fm/lIIYZ).

The new filing, U.S. Patent Application No. 19/701,742, relates to a fusion system architecture incorporating advanced housing and chamber design elements intended to support plasma confinement, pulsed energy delivery, and future commercial applications of the Texatron(TM) platform. According to the company, the filing represents part of a broader intellectual property strategy focused on protecting technologies developed during the evolution of future generations of the Texatron(TM) Fusion Engine(TM).

The announcement comes as American Fusion(TM) continues to advance its 5MW pre-production Texatron(TM) Fusion Engine(TM) program. Management reported that the system’s primary frame has been completed and that final modifications have now completed at a third-party manufacturing facility in the Midland/Odessa region of Texas. This Texatron(TM) is now safely back at the company’s homebase as preparations continue for future testing activities in the Dallas-Fort Worth Metroplex.

The company also continues to work through regulatory processes associated with planned testing. American Fusion(TM) submitted an application for certification and related approvals to the Texas Department of State Health Services in February 2026 and has reported ongoing engagement regarding licensing and certification requirements.

Beyond regulatory progress, current development activities include planning for testing facilities, acquiring specialized validation equipment, expanding the company’s patent portfolio, and establishing commercial deployment strategies for future Texatron(TM) systems. The company’s fusion strategy is being developed through its wholly owned subsidiary, Kepler Fusion Technologies.

Fusion energy remains an area of significant global research and investment because of its potential to provide long-duration, low-carbon electricity. Numerous companies are pursuing different approaches to achieving practical fusion systems, with varying engineering designs, fuel approaches, and commercialization timelines.

American Fusion(TM) is developing an aneutronic fusion approach through the Texatron(TM) Fusion Engine(TM) architecture. The company is pursuing a modular design strategy, with management indicating that multiple Texatron(TM) models are under development. According to comments from company leadership, the current development roadmap includes a 5-megawatt system intended to demonstrate the technology and several larger 10-20-30-50 and 100-megawatt designs that forms the foundation of its planned commercial-scale platform.

The modular approach is designed around standardized units that could potentially be combined to provide larger levels of power generation. For example, multiple 100-megawatt units could theoretically be deployed together to reach utility-scale energy capacity.

The company’s strategy emphasizes system engineering, intellectual property development, and creating architectures intended for long-term commercial operation. Management has stated that continued patent expansion is an important part of establishing competitive positioning as the technology progresses.

In a recent interview with Small Cap Stocks Today, Executive Chairman Brent Nelson discussed the company’s intellectual property strategy, regulatory progress, testing plans, and broader commercialization objectives. The interview formed part of the company’s ongoing effort to provide updates to investors and the market as development milestones are reached. 

“Intellectual property development, regulatory advancement, and execution of our testing roadmap remain core priorities for the company,” said Nelson. “We believe each additional patent filing strengthens the foundation of the Texatron(TM) Fusion Engine(TM) platform while supporting our broader commercialization strategy. At the same time, we continue advancing toward important testing and validation milestones that we believe will help define the next stage of the company’s development.”

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

• ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, recently appointed Pierre-Marc Gagnon, P.Eng., as the Operations Director for the Montauban Project
• Mr. Gagnon brings operational and technical expertise in drilling, field coordination, technical planning, mine operations and development, and more
• The appointment comes as continues to advance construction and operational readiness activities at its Montauban Project
• In his role, Mr. Gagnon will support site execution, operational readiness, contractor coordination, technical planning, and continued development at the Quebec facility

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, is advancing its Quebec-situated Montauban Project toward production, with construction and site preparation activities progressing as scheduled. The company is also preparing operational support systems and is installing and integrating key processing equipment. To support this progress, the company has focused on building a practical and technically capable team, recently strengthening it further with the appointment of Pierre-Marc Gagnon, P.Eng. 

Mr. Gagnon will tap into his field experience, technical expertise, and project coordination skills to enhance ESGold’s operational capabilities as the Operations Director for the Montauban Project. In this role, he will oversee and support site execution, operational readiness, contractor coordination, technical planning, and continued development at the Quebec facility. The appointment strengthens the Montauban Project’s execution team and bolsters ESGold’s focus on executing, coordinating, and advancing the infrastructure needed to support the progress toward future production (https://ibn.fm/LyGp0).

“Pierre-Marc brings practical Quebec-based operating experience at an important stage for ESGold,” said CEO Gordon Robb. “His recent hands-on experience at Eleonare, combined with his background in drilling, field coordination, technical planning, and mine operations, strengthens our execution team as we continue advancing Montauban,” he added.

Mr. Gagnon brings both operational and technical experience in the mining industry, having previously been involved in pit and underground mining, drilling, exploration, and project development. He has held roles at Dhilmar, Technologies & Services Oxx Inc., Agnico Eagle Mines Limited, FTE Drilling, Newmont Corporation, and G.E.T.T. Gold Inc. There, he developed expertise in drilling coordination, underground mine development, surveying, ground support systems, ventilation, drill-and-blast activities, material handling, technical consulting services, management of multidisciplinary teams, and coordination of field operations. 

At Dhilmar’s Eleonare Mine, for example, Mr. Gagnon was exposed to the realities of underground mine development and production, gaining a comprehensive understanding of the mining cycle. His later stint at G.E.T.T. Gold Inc. involved contributions aimed at enhancing extraction efficiency and decreasing dilution through more selective mining practices. He, therefore, “adds real field experience and technical discipline” to ESGold’s operations group, according to Mr. Robb.

Pierre-Marc’s appointment comes a few months after ESGold appointed Jason Tong, a veteran capital markets executive, as the Chief Financial Officer. At that time, Robb reiterated that the company was “assembling the operational and financial framework required to support ESGold’s next phase of growth, including production, expansion of exploration activities, and continued engagement with the capital markets.” Mr. Tong’s appointment, Robb continued, represented “another important step in that process.” It helped strengthen the company’s financial leadership and corporate structure (https://ibn.fm/mSSHZ).

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• Advances in digital health, cloud computing and data analytics are making it possible to move beyond episodic monitoring toward a more comprehensive understanding of cardiovascular health.
• HeartBeam’s proprietary HeartBeam System reflects the company’s mission to make cardiac monitoring accessible beyond the walls of a medical facility.
• The synthesized 12-lead ECG view provided by the system can help clinicians evaluate rhythm abnormalities and identify rhythm changes that may warrant additional investigation.

Cardiac monitoring is evolving beyond the routine detection of abnormal heart rhythms toward a future where patients and physicians receive timely actionable insights that can guide clinical decisions outside of a healthcare facility. As healthcare increasingly emphasizes earlier intervention and more personalized care, HeartBeam (NASDAQ: BEAT)  is developing technologies designed to transform where and how cardiac data are captured, analyzed and shared, including its proprietary, FDA-cleared HeartBeam System, the first portable, cable-free ECG system capable of synthesizing a 12-lead ECG for assessment of arrhythmias.

For decades, cardiac monitoring has relied on the standard 12-lead ECG but its use has been confined to clinical settings, requiring bulky equipment, adhesive electrodes and trained personnel to administer. This means the most clinically meaningful cardiac data is only available in a doctor’s office or hospital and rarely at the moment symptoms occur. While the 12-lead ECG remains the diagnostic standard, healthcare providers are also seeking tools that provide more timely data and context around the symptoms to support more informed treatment decisions. 

The need for better cardiac insights remains significant. According to the Centers for Disease Control and Prevention, heart disease continues to be the leading cause of death in the United States, responsible for more than 900,000 deaths each year. At the same time, many patients experience intermittent symptoms that are difficult to capture during a traditional office visit. This disconnect between where symptoms occur and where diagnostic testing is conducted can delay treatment decisions and complicate patient management.

HeartBeam’s technology is designed to address this challenge by enabling patients to capture clinically meaningful cardiac data wherever the patient is when symptoms occur. The HeartBeam System is a cable-free, high-fidelity ECG platform that captures the heart’s electrical signals from three distinct directions. The system uses embedded electrodes within a portable device to record cardiac signals without the wires and adhesive patches typically associated with traditional ECG systems.

A distinguishing feature of the platform is its ability to generate synthesized 12-lead ECG data from those recordings. In December 2025, HeartBeam received FDA clearance for the 12-lead synthesis software for arrhythmia assessment, enabling the company to provide a familiar clinical format that physicians have relied on for decades in evaluating cardiac rhythm conditions. By delivering a synthesized 12-lead ECG from a compact, patient-operated device, the company seeks to bridge the gap between traditional clinical diagnostics and remote cardiac monitoring.

The value of synthesized 12-lead data extends beyond convenience. A standard 12-lead ECG provides significantly more information than single-lead monitoring devices because it captures electrical activity from multiple perspectives. This broader view can help clinicians evaluate rhythm abnormalities and identify changes that may warrant additional investigation. Bringing this level of insight into a portable format has the potential to improve clinical decision-making when symptoms occur outside traditional healthcare settings.

Equally important is the infrastructure that surrounds the ECG data itself. HeartBeam has developed a cloud-based platform intended to support the secure transmission, storage and review of cardiac recordings. Cloud connectivity allows physicians to access patient data remotely, evaluate recordings more readily and integrate information into broader care workflows. As healthcare continues to embrace digital transformation, cloud-based systems are becoming increasingly important in enabling timely communication between patients and providers.

In addition, the company has a partnership with HeartNexus Inc., a network of board-certified cardiologists specializing in cardiac test interpretation, peer-to-peer consultations and on-demand telemedicine visits. Through this collaboration, HeartBeam can provide a 24/7 cardiology reader service designed to support patients experiencing cardiac rhythm symptoms outside of the traditional healthcare system and provide expert, timely assessment during critical moments.

“Working with HeartNexus accelerates our mission to make medical-grade cardiac monitoring accessible beyond the walls of a medical facility,” said HeartBeam CEO Robert Eno. “Together, we’re enabling patients to have the value of an ECG with timely access to a cardiologist’s interpretation in their pocket and giving physicians a powerful tool to deliver the right care at the right moment.”

This focus on actionable information mirrors broader trends across healthcare. Physicians increasingly seek technologies that not only collect data but also help prioritize, organize and contextualize that information. The ultimate goal is to reduce uncertainty and enable faster, more confident clinical decisions. For patients, that can translate into earlier intervention, fewer unnecessary visits and greater confidence in managing their health. For providers, it can mean access to more comprehensive information at the moment decisions need to be made.

As cardiac monitoring technologies continue to advance, the industry appears to be moving toward an ecosystem where diagnostics, cloud connectivity, analytics and clinical workflows are tightly integrated. The future may not simply involve detecting an arrhythmia or recording an ECG but delivering the right information to the right clinician at the right time. HeartBeam’s strategy reflects this evolution by combining portable signal acquisition, synthesized 12-lead ECG capabilities and cloud-enabled care coordination into a unified platform.

For more information about the company, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• TechForce Robotics has completed the initial deployment of its LIM-E autonomous laboratory support robot at Oncotelic Therapeutics, marking the company’s first operational entry into pharmaceutical and laboratory automation.
• The deployment fulfills Phase 1 objectives under a joint development agreement designed to evaluate robotics and AI-enhanced systems for future GMP-regulated pharmaceutical manufacturing and laboratory workflows.
• A new strategic alliance with JJ Enterprise adds advanced manufacturing, machine vision, and precision engineering expertise that could support the expansion of high-precision AI-driven applications.

Laboratory and pharmaceutical operations increasingly face the same challenge that has accelerated automation across industries from manufacturing to hospitality: how to improve efficiency while freeing highly trained personnel to focus on higher-value work. Researchers, technicians, and production staff often spend significant time on routine logistics tasks that, while necessary, do not directly advance scientific work, product development, or manufacturing output. As labor costs rise and productivity demands grow, pharmaceutical and biotechnology organizations are exploring automation solutions capable of supporting operational scalability without disrupting tightly regulated workflows.

TechForce Robotics, Inc. (“TechForce”), the acting subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), is positioning itself to address that opportunity by extending its Robotics-as-a-Service (“RaaS”) platform into pharmaceutical and laboratory automation.

Extending an Established Automation Platform

TechForce has built its platform around autonomous mobile systems designed to improve operational efficiency across commercial environments. Much of its initial focus centered on hospitality and service-industry applications, where robots transport linens, waste, supplies, and other materials throughout facilities while reducing repetitive manual tasks. The company’s latest deployment shows how that same underlying technology may be adapted for an entirely different operating environment.

In June, TechForce announced the completion of Phase 1 objectives under a joint development agreement with Oncotelic Therapeutics, Inc. (OTCQB: OTLC) through the initial deployment of LIM-E, an autonomous laboratory support robot built to assist with approved laboratory logistics workflows. The deployment marks TechForce’s first operational expansion into pharmaceutical automation and demonstrates the platform’s flexibility across industry verticals. Rather than moving hospitality materials, LIM-E is configured to transport approved laboratory supplies and properly contained materials within designated laboratory environments. The application differs from hospitality settings, but the underlying objective remains the same: improving workflow efficiency through autonomous logistics support.

The Significance of the Oncotelic Collaboration

The deployment is part of a broader collaboration aimed at evaluating how robotics and AI-enhanced automation may support future pharmaceutical manufacturing and laboratory operations. The agreement extends beyond a single deployment. The framework is intended to generate operational data, workflow observations, and performance feedback that can inform future automation initiatives within regulated pharmaceutical environments. Future areas of evaluation may include laboratory logistics, manufacturing support processes, AI-enhanced workflows, and other initiatives designed to improve consistency, efficiency, and scalability.

For organizations operating under Good Manufacturing Practice (“GMP”) requirements, even incremental workflow improvements can produce meaningful benefits. Automation that handles repetitive support functions may allow scientific personnel to dedicate more time to research, development, quality control, and manufacturing.

Why Robotics-as-a-Service Matters

One of the more notable aspects of TechForce’s strategy is its reliance on a Robotics-as-a-Service model. Robotics adoption has historically required substantial upfront capital, specialized integration, and ongoing maintenance commitments that can discourage organizations from pursuing automation. The RaaS model seeks to address those barriers by providing access to robotic systems through recurring service arrangements rather than large initial purchases.

For pharmaceutical and biotechnology organizations weighing automation initiatives, that approach may offer greater flexibility while reducing implementation risk. Companies can potentially deploy systems without significant capital commitments, while providers such as TechForce retain responsibility for support, updates, and optimization. Management believes the model can be applied across multiple industries using a common technology foundation, opening new vertical markets without requiring entirely separate robotics platforms.

Building a Multi-Industry Growth Strategy

The company’s expansion into pharmaceutical automation is also supported by efforts to strengthen its underlying engineering and manufacturing capabilities. This week, TechForce announced a strategic supply and development agreement with Taiwan-based JJ Enterprise, a precision engineering and advanced manufacturing company serving the semiconductor, automation, and specialty materials industries. Management believes the relationship will provide access to expertise in areas such as precision automation, machine vision, advanced materials processing, and semiconductor-grade manufacturing disciplines that are increasingly relevant to laboratory and pharmaceutical environments. The collaboration is expected to support future development initiatives across pharmaceutical automation, laboratory robotics, intelligent manufacturing systems, and other high-precision applications.

The pharmaceutical deployment arrives amid broader efforts to expand TechForce’s automation ecosystem and establish the engineering infrastructure needed to support increasingly sophisticated automation projects. Recent initiatives include the launch of an Enterprise Automation Division aimed at larger-scale projects and a strategic partnership with deployment provider ToDo Robotics, which has completed more than 300 robotic system deployments nationwide. Together, those moves reflect a strategy built around a diversified automation platform serving multiple sectors through robotics hardware, AI-enhanced software, deployment expertise, and recurring service relationships.

As automation adoption expands across healthcare, life sciences, logistics, and hospitality, TechForce’s pharmaceutical deployment offers an early example of how robotics platforms developed for one industry can be adapted to serve another. Combined with the company’s strategic alliance with JJ Enterprise to support advanced manufacturing and precision automation initiatives, the LIM-E deployment represents another step in TechForce’s efforts to expand its Robotics-as-a-Service platform into new high-value industrial and life sciences markets.

For more information, visit the company’s website at TechForceRobotics.com

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at https://ibn.fm/NGTF